Ohtuvayre Access Challenges: What Providers and Prescribers Need to Know in 2026

Since its FDA approval on June 26, 2024, Ohtuvayre (ensifentrine) has generated significant interest among pulmonologists, respiratory therapists, and primary care providers managing patients with moderate-to-severe COPD. Its dual PDE3/PDE4 mechanism offers a genuinely novel approach — but many prescribers are finding that patient access is not as straightforward as writing the prescription.

This guide covers the key access issues your patients are likely to encounter in 2026, and what you can do as a prescriber to help them navigate the system efficiently.

Why Ohtuvayre Access Is Challenging for Your Patients

There is no FDA-declared shortage of Ohtuvayre. However, the drug's access pathway is markedly different from conventional inhaler prescriptions. Key factors include:

Specialty pharmacy exclusivity. Ohtuvayre is not stocked at retail pharmacies. It is dispensed exclusively through accredited specialty pharmacies in the Verona Pathway Plus network.

Universal prior authorization requirements. Major payers including UnitedHealthcare and regional plans require prior authorization with clinical documentation before approving coverage.

High WAC pricing. Wholesale acquisition cost is approximately $35,400 annually ($2,950/month). ICER has issued an access and affordability alert for the drug.

Formulary placement still evolving. Many plans placed Ohtuvayre on specialty tiers requiring step therapy or extensive prior authorization. Formulary positions continue to evolve in 2025–2026.

Prior Authorization Requirements: What Documentation Is Needed

For UnitedHealthcare's commercial plans (and similar criteria are used by many payers), initial authorization for Ohtuvayre requires all of the following:

Confirmed COPD diagnosis (ICD-10)

Post-bronchodilator FEV1/FVC ratio < 0.7 (documented via spirometry)

Post-bronchodilator FEV1 % predicted ≥ 30%

Chart notes supporting medical necessity and clinical context

For reauthorization, most plans require documentation of a positive clinical response — improved symptom scores, lung function, or reduced exacerbation frequency. Begin gathering reauthorization documentation before the initial authorization period expires.

Strengthening Your Prior Authorization Submissions

To improve PA approval rates and reduce appeal burden, consider the following strategies:

Include recent spirometry results (ideally within the past 12 months) — not just the diagnosis code

Document the patient's current COPD medication regimen and symptom burden (mMRC dyspnea scale, CAT score if available)

Reference the 2025 GOLD guidelines acknowledging Ohtuvayre as add-on therapy for patients with dyspnea despite two long-acting bronchodilators

Note clinical data from the ENHANCE-1 and ENHANCE-2 trials demonstrating significant FEV1 improvement and reduced exacerbations

Highlight the unique steroid-free mechanism for patients where ICS use is contraindicated or undesirable

Appropriate Patient Selection in 2026

Ohtuvayre is FDA-approved for the maintenance treatment of COPD in adult patients. Based on the ENHANCE trial populations and the 2025 GOLD guidelines, the strongest candidates for Ohtuvayre include:

Patients with moderate to severe COPD (FEV1 30–79% predicted) experiencing persistent dyspnea despite current therapy

Patients on LABA ± ICS or LAMA ± ICS who need additional symptom relief (Ohtuvayre demonstrated benefit as add-on to these regimens in ENHANCE)

Patients where inhaled corticosteroids are undesirable (pneumonia risk, osteoporosis, diabetes) — Ohtuvayre provides anti-inflammatory effects without steroids

Patients already on or comfortable with nebulizer therapy (e.g., those who use albuterol nebulization at home)

Note that the ENHANCE trials excluded patients on dual bronchodilator therapy (LABA/LAMA), so evidence is more limited in that population. Also screen patients for psychiatric history before initiating — Ohtuvayre carries a warning for psychiatric adverse reactions including suicidality.

Key Warnings and Monitoring Points for Prescribers

Psychiatric adverse events: Treatment with Ohtuvayre is associated with increased psychiatric adverse reactions including insomnia (0.6%), anxiety (0.2%), depression (0.4%), and rare suicide-related events. Screen patients with psychiatric history carefully. Counsel patients and caregivers to report mood changes.

Hepatic impairment: Ensifentrine systemic exposure increases 2.3-fold in moderate-to-severe hepatic impairment. Use with caution; no dose adjustment guidance exists in this population.

Paradoxical bronchospasm: As with other inhaled therapies, Ohtuvayre may cause paradoxical bronchospasm. If this occurs, discontinue immediately and treat with a short-acting bronchodilator.

Not for acute bronchospasm: Ensure patients understand Ohtuvayre is a maintenance medication only. They must have a short-acting rescue bronchodilator (e.g., albuterol) available for acute exacerbations.

Verona Pathway Plus: Your Practice's Support Resource

Verona Pathway Plus (1-833-372-8492) offers a suite of services to help your office navigate the Ohtuvayre access pathway:

Benefit verification and prior authorization coordination

Specialty pharmacy assignment and prescription routing

Copay assistance enrollment for commercially insured patients ($0/month copay eligible)

Patient assistance for uninsured/underinsured patients

Appeal support if coverage is initially denied

How medfinder Supports Your Patients

Once a patient's prior authorization is approved and they're working with a specialty pharmacy, locating which pharmacy currently has Ohtuvayre in stock can still be challenging. medfinder for providers can help: medfinder calls pharmacies on behalf of patients to check which ones can fill the prescription, then texts results directly to the patient. This is particularly useful for COPD patients with functional limitations who struggle to spend hours on the phone.

Clinical Takeaways for 2026

Ohtuvayre is the first inhaled COPD maintenance drug with a novel mechanism in over 20 years — appropriate for select patients with moderate-to-severe COPD who need additional symptom control

Specialty pharmacy and prior authorization are required; submit documentation promptly and comprehensively

Enroll patients in Verona Pathway Plus at the time of prescribing to reduce delays

Screen for psychiatric history before prescribing; monitor for mood changes after initiation

Use caution in patients with moderate-to-severe hepatic impairment

See also our provider guide: How to Help Your Patients Find Ohtuvayre In Stock.